Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer

A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer Purpose Intravesical chemotherapy administered within 24 h of the first resection of non-muscle-invasive bladder cancer (NMIBC) reduces recurrence rates and prolongs recurrence-free intervals. However, there is considerable variation in the use of intravesical chemotherapy amongst urologists. In our hospital, we use mitomycin C (MMC), and our usage was inconsistent. Therefore, we devised a care bundle to improve MMC usage. The objective of this study was to evaluate the effectiveness of the care bundle on postoperative MMC use. Methods We measured baseline postoperative MMC use during the first quarter of 2013. In 2014, we implemented a care bundle by changing MMC delivery, through computer-based clinical information systems and repeated training of key stake- holders. We studied the performance of the bundle through snapshot audits in the last quarter of 2014, a 6-month period in the middle of 2015 and again in the final quarter of 2016. Results We observed an increase in intravesical chemotherapy usage after implementing the care bundle. Instillation rates in our samples increased from 46% (6/13), in 2013 to 89% (8/9), in 2014, 90% (9/10), in 2015 and 100% (12/12), in 2016. Conclusion Compliance rates of intravesical chemotherapy in NMIBC can improve by devising care bundles to modify http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Urology and Nephrology Springer Journals

A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer

Download PDF
7 pages

Loading next page...
 
/lp/springer_journal/a-care-bundle-to-improve-perioperative-mitomycin-use-in-non-muscle-mZVyHlcyxY
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Science+Business Media B.V., part of Springer Nature
Subject
Medicine & Public Health; Nephrology; Urology
ISSN
0301-1623
eISSN
1573-2584
DOI
10.1007/s11255-018-1863-4
pmid
29611146
Publisher site
See Article on Publisher Site

Abstract

Purpose Intravesical chemotherapy administered within 24 h of the first resection of non-muscle-invasive bladder cancer (NMIBC) reduces recurrence rates and prolongs recurrence-free intervals. However, there is considerable variation in the use of intravesical chemotherapy amongst urologists. In our hospital, we use mitomycin C (MMC), and our usage was inconsistent. Therefore, we devised a care bundle to improve MMC usage. The objective of this study was to evaluate the effectiveness of the care bundle on postoperative MMC use. Methods We measured baseline postoperative MMC use during the first quarter of 2013. In 2014, we implemented a care bundle by changing MMC delivery, through computer-based clinical information systems and repeated training of key stake- holders. We studied the performance of the bundle through snapshot audits in the last quarter of 2014, a 6-month period in the middle of 2015 and again in the final quarter of 2016. Results We observed an increase in intravesical chemotherapy usage after implementing the care bundle. Instillation rates in our samples increased from 46% (6/13), in 2013 to 89% (8/9), in 2014, 90% (9/10), in 2015 and 100% (12/12), in 2016. Conclusion Compliance rates of intravesical chemotherapy in NMIBC can improve by devising care bundles to modify

Journal

International Urology and Nephrology – Springer Journals

Published: Apr 2, 2018

References

  • Management of non-muscle-invasive (superficial) bladder cancer
    Nargund, VH; Tanabalan, CK; Kabir, MN
  • Pathobiology and chemoprevention of bladder cancer
    Tanaka, T; Miyazawa, K; Tsukamoto, T; Kuno, T; Suzuki, K
  • The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up
    Tolley, DA; Parmar, MK; Grigor, KM; Lallemand, G; Benyon, LL; Fellows, J; Freedman, LS; Grigor, KM; Hall, RR; Hargreave, TB; Munson, K; Newling, DW; Richards, B; Robinson, MR; Rose, MB; Smith, PH; Williams, JL; Whelan, P
  • Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review
    Perlis, N; Zlotta, AR; Beyene, J; Finelli, A; Fleshner, NE; Kulkarni, GS
  • Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate posttransurethral resection of the bladder chemoprophylaxis
    Lykke, MR; Nielsen, TK; Ebbensgaard, NA; Zieger, K
  • Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial
    Nunzio, C; Carbone, A; Albisinni, S; Alpi, G; Cantiani, A; Liberti, M; Tubaro, A; Iori, F
  • A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials
    Sylvester, RJ; Oosterlinck, W; Meijden, AP
  • Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer
    Cockerill, PA; Knoedler, JJ; Frank, I; Tarrell, R; Karnes, RJ
  • EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013
    Babjuk, M; Burger, M; Zigeuner, R; Shariat, SF; Rhijn, BW; Compérat, E; Sylvester, RJ; Kaasinen, E; Böhle, A; Palou Redorta, J; Rouprêt, M
  • A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group
    Brausi, M; Witjes, JA; Lamm, D; Persad, R; Palou, J; Colombel, M; Buckley, R; Soloway, M; Akaza, H; Böhle, A
  • Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors
    Madeb, R; Golijanin, D; Noyes, K; Fisher, S; Stephenson, JJ; Long, SR; Knopf, J; Lyman, GH; Messing, EM
  • Compliance with guidelines for patients with bladder cancer: variation in the delivery of care
    Chamie, K; Saigal, CS; Lai, J; Hanley, JM; Setodji, CM; Konety, BR; Litwin, MS
  • Mitomycin C for the treatment of bladder cancer
    Volpe, A; Racioppi, M; D’Agostino, D; Cappa, E; Filianoti, A; Bassi, PF
  • Methods to improve efficacy of intravesical mitomycin C: results of a randomised phase III trial
    Au, JL; Badalament, RA; Wientjes, MG
  • All-or-none measurement raises the bar on performance
    Nolan, T; Berwick, DM
  • Improving compliance with a single post-operative dose of intravesical chemotherapy after transurethral resection of bladder tumour
    Stroman, L; Tschobotko, B; Abboudi, H; Ellis, D; Mensah, E; Kaneshayogan, H; Mazaris, E
  • Clinical practice pattern of immediate intravesical chemotherapy following transurethral resection of a bladder tumor in Korea: National Health Insurance Database Study
    Seo, GH; Kim, JH; Ku, JH
  • Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA)
    Gan, C; Patel, A; Fowler, S; Catto, J; Rosario, D; O’Brien, T
  • Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle-invasive bladder cancer (NMIBC) treatment
    Neuzillet, Y; Colin, P; Comperat, E; Dubosq, F; Houede, N; Larre, S; Masson-Lecomte, A; Pignot, G; Puech, P; Roumiguie, M; Xylinas, E; Mejean, A; Roupret, M
  • Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey
    Nielsen, ME; Smith, AB; Pruthi, RS; Guzzo, TJ; Amiel, G; Shore, N; Lotan, Y
  • Reported patterns of utilization of intravesical therapy in non-muscle-invasive bladder cancer: results from the BCAN/SUO/AUA/LUGPA electronic survey
    Smith, A; Nielsen, ME; Manvar, A; Ferguson, J; Pruthi, R; Wallen, E; Lotan, Y
  • National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer
    Cookson, MS; Chang, SS; Oefelein, MG; Gallagher, JR; Schwartz, B; Heap, K
  • Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline
    Chang, SS; Boorjian, SA; Chou, R; Clark, PE; Daneshmand, S; Konety, BR; Pruthi, R; Quale, DZ; Ritch, CR; Seigne, JD; Skinner, EC; Smith, ND; McKiernan, JM
  • Systematic review and individual patient data meta-analysis of randomised trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?
    Sylvester, RJ; Oosterlinek, W; Holmang, S; Sydes, MR; Birtle, A; Gudjonsson, S; Nunzio, C; Okamura, K; Kaasinen, E; Solsona, E; Ali-El-Dein, B; Tatar, CA; Inman, BA; N’Dow, J; Oddens, JR; Babjuk, M
  • Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients
    Bosschieter, J; Nieuwenhuijzen, JA; Ginkel, T; Vis, AN; Witte, B; Newling, D; Beckers, GMA; Moorselaar, RJA